Archive · 31 Dec 2025
India Bans High-Dose Nimesulide Oral Medications
The Indian government has banned the sale and distribution of high-dose Nimesulide oral medications, which are pain and fever drugs.
This ban is because these high doses might be harmful to the liver and have other bad effects.
The ban only applies to doses above 100 mg, and lower doses are still allowed.
The government says there are safer alternatives available.
Big drug companies might not be affected much, but smaller ones that sell a lot of Nimesulide might have some problems.
India has also been investing a lot of money to make more of the important ingredients needed to make medicines, so they don't have to rely on other countries as much.
India has banned the manufacture, sale, and distribution of oral Nimesulide formulations above 100 mg in immediate-release dosage form.
The ban is based on potential liver toxicity and other adverse effects, with safer alternatives available.
Only high-dose products for human use are banned, while lower-dose formulations remain available.
Pharmaceutical companies must halt production and recall impacted batches, with limited financial impact expected on large drugmakers.
India has invested significantly in domestic active pharmaceutical ingredient manufacturing to reduce supply disruption risks.
- Who
- Indian Health Ministry and Drugs Technical Advisory Board
- What
- Ban on high-dose Nimesulide oral medications
- When
- Immediate effect
- Where
- India
- Why
- Potential liver toxicity and other adverse effects, with safer alternatives available
Health and Safety Advocates
Pharmaceutical Industry
Ban Justification
Health and Safety Advocates
The ban is necessary to protect public health due to potential liver toxicity and other adverse effects of high-dose Nimesulide.
Pharmaceutical Industry
The ban may disproportionately affect smaller pharmaceutical companies that rely heavily on Nimesulide sales, potentially leading to revenue pressure.
- Drug
- Nimesulide (oral formulations above 100 mg)
- Action
- Ban on manufacture, sale, and distribution
- Effective Date
- Immediate
- Authority
- Health Ministry, Drugs Technical Advisory Board
- Reason
- Potential liver toxicity and other adverse effects
- Impact
- Limited financial impact on large drugmakers, potential revenue pressure on smaller firms
- Alternatives
- Lower-dose formulations and other therapeutic options available
- PLI Scheme Investment
- Rs 4,763.34 crore (till September 2025)
Sources
Health Ministry Bans Nimesulide Oral Doses Above 100 Mg Over Safety Concerns
India bans oral Nimesulide over 100 mg
Nimesulide ban: Govt bars sale of oral painkiller doses above 100 mg
Govt bans manufacture, sale of oral formulations containing nimesulide above 100 mg-Here's why
Health Ministry bans oral formulations of painkiller nimesulide above 100 mg, cites safety risks
Health Ministry Bans Nimesulide Oral Doses Above 100 Mg Over Safety Concerns
Centre Bans High-Dose Nimesulide Oral Formulations
Health Ministry bans nimesulide oral tablets, syrups over 100 mg, removes cough syrups from OTC sales
Nimesulide oral formulations of over 100 mg banned by the central government due to health risks
Centre bans oral formulations of popular painkiller Nimesulide over 100 mg
